Bristol Myers Squibb (BMY) Q1 2024 Earnings Call Transcript
BMY earnings call for the period ending March 31, 2024.
Source: fool.com
Adam Lenkowsky News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Adam Lenkowsky. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Adam Lenkowsky Today - Breaking & Trending Today
Bristol Myers Squibb (BMY) Q4 2023 Earnings Call Transcript
BMY earnings call for the period ending December 31, 2023.
Source: yahoo.com
Bristol Myers posts better-than-expected 4th-quarter results
Drugmaker Bristol Myers Squibb on Friday posted better-than-expected results for the fourth quarter as sales of its new anemia drug Reblozyl and its already off patent blood cancer drug Revlimid...
Source: marketscreener.com
Bristol Myers Squibb (BMY) Q4 2023 Earnings Call Transcript
BMY earnings call for the period ending December 31, 2023.
Source: fool.com
Rather fight than switch in schizophrenia: Karuna smokin' with $14B deal as BMS gains Karxt
Adam Lenkowsky, chief commercial officer for Bristol Myers Squibb Co. (BMS), said his firm plans to launch Karxt (xanomeline-trospium) in the U.S. as soon as it’s approved by the U.S. FDA, and “expect[s] to accumulate sales in early 2025.” BMS tied a bow on the year by disclosing its plan to pay $330 per share to take over Karuna Therapeutics Inc. in a deal valued at $14 billion to bring aboard Karxt, which acts as a dual M1/M4 muscarinic acetylcholine receptor agonist. The FDA has assigned Sept. 26, 2024, as the PDUFA date for Karxt as a new treatment for schizophrenia in adults.
Source: bioworld.com